Pfizer Secures $2B for COVID-19 Vaccine, BioNTech Raises $500M, & Our Test

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.


You may also like

J&J Vaccine Study Paused, Lilly Antibody Paused, and Regeneron’s Ebola FDA Approval
A Historic Nobel for CRISPR, Pfizer Sticks Up for FDA, & a CDC Legend Speaks
FDA Commissioners Speak Out, An Antibiotic Incentive Proposal and a Drug Price Grilling
Illumina’s Bet on Early Cancer Detection & ESMO Highlights